The double-blinded, randomized, placebo-controlled, dose ranging study is designed to evaluate the drug in about 180 pre-menopause obese women. The study is intended to confirm and extend previous
In this study, the therapeutic efficacy of SN-38 conjugated to labetuzumab was evaluated in two animal models of human colon cancer. Labetuzumab is a non-internalizing humanized antibody that
The agreement provides for potential modification of select terms based on certain events and developments. The specific financial terms and conditions of the agreement have not been disclosed.
The technology is incorporated in the company’s AtherOx product group, a next-generation technology to identify individuals at risk for developing atherosclerotic cardiovascular disease. According to the company, the
Under the licensing agreement, Celldex has granted a worldwide fee- and royalty-bearing exclusive license to Vaccine Technologies (VTI) to develop and commercialize Celldex’s CholeraGarde and enterotoxigenic Escherichia coli
Grass Neurotrac III software has received the 510(k) clearance for the intended use of recording the electroencephalogram (EEG) and the computed EEG trends over extended periods of time
The testing performed by Accu-Chem includes analyses of body fluids and tissues for recognized toxic chemicals including chlorinated pesticides, volatile solvents, and polychlorinated biphenyls. These tests, which will
The AZ-104 Phase IIb clinical trial is an outpatient, multi-center, randomized, double-blind, single-dose, placebo-controlled study in approximately 360 patients who have migraines, with or without aura. Approximately three
Abraxis BioScience will be solely dedicated to building its Abraxane franchise on a global basis, advancing an extensive Phase III clinical program, and leveraging its proprietary nab technology
If the extension is approved, 3SBio expects that TPIAO for idiopathic thrombocytopenic purpura (ITP) will be the only treatment of this kind available in China. Launched in 2006,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.